JP2022516957A5 - - Google Patents
Info
- Publication number
- JP2022516957A5 JP2022516957A5 JP2021539682A JP2021539682A JP2022516957A5 JP 2022516957 A5 JP2022516957 A5 JP 2022516957A5 JP 2021539682 A JP2021539682 A JP 2021539682A JP 2021539682 A JP2021539682 A JP 2021539682A JP 2022516957 A5 JP2022516957 A5 JP 2022516957A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195562A JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789828P | 2019-01-08 | 2019-01-08 | |
| US62/789,828 | 2019-01-08 | ||
| US201962840967P | 2019-04-30 | 2019-04-30 | |
| US62/840,967 | 2019-04-30 | ||
| US201962841585P | 2019-05-01 | 2019-05-01 | |
| US62/841,585 | 2019-05-01 | ||
| US201962872983P | 2019-07-11 | 2019-07-11 | |
| US62/872,983 | 2019-07-11 | ||
| PCT/US2020/012790 WO2020146535A1 (en) | 2019-01-08 | 2020-01-08 | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195562A Division JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516957A JP2022516957A (ja) | 2022-03-03 |
| JPWO2020146535A5 JPWO2020146535A5 (https=) | 2022-12-13 |
| JP2022516957A5 true JP2022516957A5 (https=) | 2022-12-13 |
Family
ID=71404208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539682A Withdrawn JP2022516957A (ja) | 2019-01-08 | 2020-01-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
| JP2024195562A Pending JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195562A Pending JP2025032102A (ja) | 2019-01-08 | 2024-11-08 | 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20200216525A1 (https=) |
| EP (1) | EP3908607A4 (https=) |
| JP (2) | JP2022516957A (https=) |
| KR (1) | KR20210114002A (https=) |
| CN (2) | CN119303074A (https=) |
| AU (1) | AU2020207299A1 (https=) |
| BR (1) | BR112020018044A2 (https=) |
| CA (1) | CA3123292A1 (https=) |
| CL (1) | CL2021001813A1 (https=) |
| CO (1) | CO2021008665A2 (https=) |
| DO (1) | DOP2021000145A (https=) |
| EC (1) | ECSP21052193A (https=) |
| GE (2) | GEP20257804B (https=) |
| IL (1) | IL284677A (https=) |
| JO (1) | JOP20210166A1 (https=) |
| MA (1) | MA54709A (https=) |
| MX (1) | MX2021008268A (https=) |
| NI (1) | NI202100063A (https=) |
| PE (1) | PE20211708A1 (https=) |
| PH (1) | PH12021551494A1 (https=) |
| SG (1) | SG11202106878XA (https=) |
| TW (1) | TW202030205A (https=) |
| UA (1) | UA129265C2 (https=) |
| WO (1) | WO2020146535A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012258980B8 (en) | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| NZ717704A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN113227140A (zh) | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| EP4392447A1 (en) * | 2021-08-27 | 2024-07-03 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
| WO2024032750A1 (zh) * | 2022-08-11 | 2024-02-15 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
| CN118476508A (zh) * | 2024-06-27 | 2024-08-13 | 中国人民解放军总医院第一医学中心 | 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| AU2012258980B8 (en) * | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) * | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| CN103585449B (zh) * | 2013-10-23 | 2016-06-22 | 高丽丽 | 用于治疗偏头痛的中药组合物 |
| CA2982861A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| WO2018055574A1 (en) * | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| CN113227140A (zh) * | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
-
2020
- 2020-01-08 PE PE2021001141A patent/PE20211708A1/es unknown
- 2020-01-08 CN CN202411285298.5A patent/CN119303074A/zh active Pending
- 2020-01-08 CA CA3123292A patent/CA3123292A1/en active Pending
- 2020-01-08 GE GEAP202015689A patent/GEP20257804B/en unknown
- 2020-01-08 MA MA054709A patent/MA54709A/fr unknown
- 2020-01-08 WO PCT/US2020/012790 patent/WO2020146535A1/en not_active Ceased
- 2020-01-08 US US16/736,937 patent/US20200216525A1/en not_active Abandoned
- 2020-01-08 GE GEAP202515689A patent/GEAP202515689A/en unknown
- 2020-01-08 JP JP2021539682A patent/JP2022516957A/ja not_active Withdrawn
- 2020-01-08 CN CN202080007409.XA patent/CN113272324A/zh active Pending
- 2020-01-08 EP EP20738512.1A patent/EP3908607A4/en active Pending
- 2020-01-08 AU AU2020207299A patent/AU2020207299A1/en active Pending
- 2020-01-08 JO JOP/2021/0166A patent/JOP20210166A1/ar unknown
- 2020-01-08 BR BR112020018044-0A patent/BR112020018044A2/pt unknown
- 2020-01-08 KR KR1020217023581A patent/KR20210114002A/ko active Pending
- 2020-01-08 MX MX2021008268A patent/MX2021008268A/es unknown
- 2020-01-08 TW TW109100630A patent/TW202030205A/zh unknown
- 2020-01-08 PH PH1/2021/551494A patent/PH12021551494A1/en unknown
- 2020-01-08 SG SG11202106878XA patent/SG11202106878XA/en unknown
- 2020-01-08 UA UAA202104194A patent/UA129265C2/uk unknown
-
2021
- 2021-06-30 CO CONC2021/0008665A patent/CO2021008665A2/es unknown
- 2021-07-07 CL CL2021001813A patent/CL2021001813A1/es unknown
- 2021-07-07 DO DO2021000145A patent/DOP2021000145A/es unknown
- 2021-07-07 IL IL284677A patent/IL284677A/en unknown
- 2021-07-07 NI NI202100063A patent/NI202100063A/es unknown
- 2021-07-14 EC ECSENADI202152193A patent/ECSP21052193A/es unknown
-
2023
- 2023-11-16 US US18/511,241 patent/US20240343784A1/en active Pending
-
2024
- 2024-11-08 JP JP2024195562A patent/JP2025032102A/ja active Pending